Zhuhai People's Hospital (Zhuhai hospital affiliated with Jinan University), Zhuhai 519000, China.
College of Pharmacy, Jinan University, Guangzhou 510632, China.
Eur J Hosp Pharm. 2022 May;29(3):129-133. doi: 10.1136/ejhpharm-2020-002447. Epub 2020 Nov 3.
Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis.
Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis.
A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD -1.39, 95% CI -2.50 to -0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD -0.92, 95% CI -1.59 to -0.24; p<0.05) than the control group.
Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis.
近年来，他克莫司已广泛用于治疗过敏性结膜炎，但目前尚无关于其疗效的荟萃分析。本研究系统评价了他克莫司治疗过敏性结膜炎的疗效。
通过结合医学主题词和自由词，从 PubMed、Cochrane Library、Embase、CNKI 和万方数据库中检索文献数据。根据既定的纳入和排除标准选择文献，并使用 RevMan 5.3 评估提取数据的偏倚风险进行荟萃分析。
共检索到 177 篇文章，最终选择了 5 篇文章，均涉及他克莫司治疗春季角结膜炎。共分析了 203 个样本。荟萃分析结果显示，他克莫司治疗组眼客观体征评分明显降低（SMD-1.39，95%CI-2.50 至-0.27；p<0.05），主观症状评估评分明显降低（SMD-0.92，95%CI-1.59 至-0.24；p<0.05），均显著低于对照组。
现有证据表明，他克莫司治疗春季角结膜炎有效。
